KEY POINTS
- This retrospective single-center series included 285 patients treated with insurance-covered boron neutron capture therapy in Japan between 2020 and 2024 for unresectable locally advanced or recurrent head and neck cancer. The cohort was heavily pretreated: 81.1% had received prior radiotherapy, 66.3% chemotherapy, 48.8% surgery, and 28.3% an immune checkpoint inhibitor.
- BNCT used intravenous borofalan followed by accelerator-based neutron irradiation. Curative-intent planning required GTV D80% ≥20 Gy-Eq, while normal-tissue limits included 15 Gy-Eq to skin, 12 Gy-Eq to pharyngeal mucosa D5%, 9 Gy-Eq to brain, and 5 Gy-Eq to the eye.
- Best overall response was 47.0% complete response and 33.3% partial response, producing an objective response rate of 80.4%. Stable disease occurred in 11.6% and progressive disease in 7.0%.
- Despite the high initial response rate, durability was more modest: local control was 52.5% at one year and 41.5% at two years, while two-year progression-free survival was 26.4%. Median local control and progression-free survival were 13.3 and 8.8 months, respectively.
- Overall survival was 78.6% at one year and 59.2% at two years, with a median OS of 33.5 months. Local control and PFS did not differ significantly between squamous and non-squamous histologies, although non-squamous cancers had significantly better OS.
- Disease extent at the time of BNCT mattered. In squamous cell carcinoma, more advanced T and N categories were associated with poorer local control; the Cox analysis showed particularly unfavorable local control for T3–4 disease and N3 disease, supporting treatment before extensive local progression.
- Clinically important toxicity remained substantial in this heavily pretreated population. The two-year cumulative incidence of grade ≥3 late toxicity was 14.0%, and grade 5 events occurred in 2.1%, including three fatal pharyngeal hemorrhages, one esophageal perforation, one cranial nerve infection, and one sepsis.
CLINICAL TAKEAWAY
BNCT can produce a high initial response rate in selected patients with unresectable or recurrent head and neck cancer, including many who have already received full-dose radiotherapy. However, durable local control remains limited and serious late toxicity, including fatal events, is not negligible; these real-world data support BNCT as a specialized salvage option rather than evidence of superiority over modern reirradiation strategies.